{"gene":"ARID2","run_date":"2026-06-09T22:02:44","timeline":{"discoveries":[{"year":2005,"finding":"ARID2 (BAF200) is a specificity subunit of the PBAF chromatin-remodeling complex (SWI/SNF family) required for selective transcriptional activation of interferon-responsive genes; PBAF and BAF regulate expression of distinct gene sets, and this selectivity requires BAF200 but not the previously described PBAF-specificity subunit BAF180.","method":"Biochemical complex purification, in vivo gene expression studies comparing PBAF vs BAF complex activity on interferon-responsive gene promoters","journal":"Genes & development","confidence":"High","confidence_rationale":"Tier 2 / Strong — multiple orthogonal methods (complex purification, in vivo transcription assays), foundational study identifying ARID2 as PBAF subunit with specific function","pmids":["15985610"],"is_preprint":false},{"year":2014,"finding":"BAF200 (ARID2) is required for heart morphogenesis and coronary artery development in vivo; BAF200 mutant mice are embryonic lethal with thin myocardium, ventricular septum defect, common atrioventricular valve, double outlet right ventricle, and reduced intramyocardial coronary arteries, indicating a role in migration and differentiation of subepicardial venous cells into arterial endothelial cells.","method":"BAF200 mutant mouse generation (conditional knockout), histology, embryonic phenotype analysis","journal":"PloS one","confidence":"High","confidence_rationale":"Tier 2 / Strong — clean in vivo knockout with specific and reproducible cardiac phenotypic readout","pmids":["25299188"],"is_preprint":false},{"year":2016,"finding":"ARID2 suppresses hepatoma cell proliferation and tumor growth by physically interacting with E2F1 and decreasing E2F1/RNA Pol II binding to the promoters of CCND1 (cyclin D1) and CCNE1 (cyclin E1), thereby repressing their transcription and retarding G1/S cell cycle progression.","method":"Co-immunoprecipitation (physical interaction with E2F1), ChIP assay (E2F1/RNA Pol II binding to CCND1/CCNE1 promoters), gain/loss-of-function proliferation assays, mouse xenograft tumor growth","journal":"Oncotarget","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — Co-IP plus ChIP establishing promoter occupancy mechanism, single lab with two orthogonal methods","pmids":["27351279"],"is_preprint":false},{"year":2017,"finding":"ARID2 is required for nucleotide excision repair (NER): ARID2 knockout in HCC cells attenuates NER at UV-induced and chemically induced DNA damage sites because XPG (xeroderma pigmentosum group G protein) cannot accumulate without ARID2, resulting in susceptibility to carcinogens and increased somatic mutation burden.","method":"CRISPR/Cas9 ARID2 knockout, gene expression profiling, UV irradiation sensitivity assays, XPG recruitment assay, large-scale public dataset validation","journal":"Journal of hepatology","confidence":"High","confidence_rationale":"Tier 2 / Strong — CRISPR KO with mechanistic follow-up (XPG recruitment) and validation in public datasets; multiple orthogonal approaches","pmids":["28238438"],"is_preprint":false},{"year":2017,"finding":"Baf200 (ARID2) facilitates homologous recombination-dependent DNA double-strand break (DSB) repair by recruiting Rad51 to DSBs; Baf200 and Rad51 are present in the same complex mediated by C-terminal sequences in both proteins. Baf200 also forms at least two distinct PBAF complexes: one canonical form containing BRG1, and another containing Baf180 but not BRG1.","method":"Cytological and biochemical approaches (co-immunoprecipitation, homology-directed repair assays, Rad51 recruitment assays, cell survival after DNA damage)","journal":"The Journal of biological chemistry","confidence":"High","confidence_rationale":"Tier 2 / Strong — reciprocal Co-IP, functional HR assay, and identification of two distinct complexes in a single rigorous study","pmids":["28381560"],"is_preprint":false},{"year":2018,"finding":"Baf200 (ARID2) is required for fetal hematopoietic stem cell (HSC) expansion and erythropoiesis; Tie2-Cre-mediated loss causes perinatal death from defective erythropoiesis; conditional knockout HSCs show impaired long-term reconstitution potential in transplantation assays; loss of Baf200 in MLL-AF9-driven leukemia accelerates tumor burden, indicating a tumor suppressor role in hematopoiesis.","method":"Tie2-Cre, Vav-iCre, Mx1-Cre conditional knockouts, fetal liver/bone marrow transplantation, RNA-seq, cell cycle/apoptosis assays, MLL-AF9 leukemia mouse model","journal":"Journal of hematology & oncology","confidence":"High","confidence_rationale":"Tier 2 / Strong — multiple Cre systems and transplantation assays with specific hematopoietic phenotypes, multiple orthogonal methods","pmids":["29482581"],"is_preprint":false},{"year":2019,"finding":"HBV core protein (HBc) physically interacts with BAF200 (ARID2) C-terminus, disrupting PBAF complex stability; this interaction suppresses IFITM1 transcription, where basal IFITM1 expression depends on BAF200 rather than the JAK-STAT1 pathway. HBc-mediated PBAF disruption thus inhibits IFNα-induced IFITM1 expression, contributing to HBV immune evasion.","method":"Yeast two-hybrid (initial identification), co-immunoprecipitation in 293T, HepG2, HepG2-NTCP cells, IFITM1 luciferase/expression assays, HBV replication assays","journal":"Viruses","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — reciprocal Co-IP in multiple cell lines, functional validation of IFITM1 suppression, single lab","pmids":["31075894"],"is_preprint":false},{"year":2020,"finding":"ARID2 suppresses HCC metastasis and epithelial-mesenchymal transition (EMT) by recruiting DNMT1 to the Snail promoter, increasing promoter methylation and inhibiting Snail transcription. ARID2 mutants with disrupted C2H2 domain lose this metastasis suppressor function.","method":"ARID2 KO in HCC mouse models, in vitro migration/invasion assays, in vivo metastasis assays, ChIP assay (DNMT1 recruitment to Snail promoter), bisulfite sequencing (promoter methylation), domain mutant functional analysis","journal":"Proceedings of the National Academy of Sciences of the United States of America","confidence":"High","confidence_rationale":"Tier 2 / Strong — multiple orthogonal methods (KO mouse models, ChIP, bisulfite sequencing, domain mutagenesis) in a single rigorous study","pmids":["32071245"],"is_preprint":false},{"year":2020,"finding":"ARID2 is a pomalidomide-induced neosubstrate of the CRL4CRBN E3 ubiquitin ligase complex; pomalidomide induces ARID2 degradation in multiple myeloma cells, and BRD7 (another PBAF subunit) is critical for this pomalidomide-induced ARID2 degradation. ARID2 regulates transcription of pomalidomide target genes including MYC.","method":"Proteomics, co-immunoprecipitation, BRD7 knockdown, pomalidomide treatment with protein degradation assays, MYC expression assays, proliferation assays","journal":"Nature chemical biology","confidence":"High","confidence_rationale":"Tier 2 / Strong — multiple orthogonal methods (proteomics, Co-IP, functional degradation assays, BRD7 dependency), rigorous mechanistic characterization","pmids":["32958952"],"is_preprint":false},{"year":2020,"finding":"ARID2 deficiency leads to STAT1 upregulation, which subsequently causes increased expression of T-cell-attracting chemokines CXCL9, CXCL10, and CCL5, sensitizing melanoma to anti-PD-L1 immune checkpoint inhibitors with increased CD8+ T cell infiltration.","method":"ARID2 knockout in melanoma cells, in vivo anti-PD-L1 treatment, flow cytometry (CD8+ T cell infiltration), gene expression analysis","journal":"The Journal of investigative dermatology","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — in vivo KO with functional immune readout and mechanistic gene expression link, single lab","pmids":["33333124"],"is_preprint":false},{"year":2020,"finding":"Loss of Arid2 in HSCs impairs lymphoid lineage differentiation in a cell-autonomous manner; Arid2 knockout enriches myeloid-biased MPP signatures while depleting lymphoid-biased MPPs, and upregulates inflammatory pathways including TLR receptors and downstream signaling genes.","method":"Conditional Arid2 knockout mouse, bone marrow transplantation, RNA-seq, in vitro lymphocyte growth assays with LPS stimulation","journal":"Experimental hematology","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — conditional KO with transplantation and RNA-seq, single lab","pmids":["33346030"],"is_preprint":false},{"year":2021,"finding":"ARID2 deficiency promotes lung adenocarcinoma progression; through ChIP-seq and RNA-seq integration, Hspa1a was identified as upregulated by Arid2 loss, and HSPA1A knockdown specifically inhibits malignant progression of Arid2-deficient but not Arid2-wild-type lung cancers in cell lines and animal models.","method":"Kras-based genetically engineered mouse models, ARID2 KO, ChIP-seq, RNA-seq, HSPA1A knockdown, HSPA1A inhibitor treatment, in vivo tumor models","journal":"National science review","confidence":"High","confidence_rationale":"Tier 2 / Strong — integrative ChIP-seq/RNA-seq with functional KO and inhibitor validation in both cells and animal models","pmids":["34858604"],"is_preprint":false},{"year":2022,"finding":"ARID2 mitigates hepatic steatosis by repressing JAK2-STAT5-PPARγ signaling; ARID2 promotes ubiquitination and degradation of JAK2 via NEDD4L (an E3 ligase for JAK2). Mechanistically, ARID2 recruits CARM1 to increase H3R17me2a at the NEDD4L promoter, activating NEDD4L transcription.","method":"Liver-specific Arid2 KO mouse (including HFD model), ChIP assay (CARM1 and H3R17me2a at NEDD4L promoter), ubiquitination assays, JAK2 inhibitor (Fedratinib) rescue, co-immunoprecipitation","journal":"Cell death and differentiation","confidence":"High","confidence_rationale":"Tier 2 / Strong — in vivo KO with ChIP, ubiquitination assay, inhibitor rescue, and clinical sample validation; multiple orthogonal methods in single study","pmids":["36396719"],"is_preprint":false},{"year":2022,"finding":"BRD4 inhibition (JQ1) induces synthetic lethality in ARID2-deficient HCC cells by exacerbating DNA double-strand breaks; both ARID2 and BRD4 synergistically maintain transcriptional enhancer-promoter loops for BRCA1, RAD51, and 53BP1, and loss of both impairs their expression, preventing DSB repair.","method":"High-throughput drug screening, JQ1 treatment in ARID2-depleted HCC cells, DNA damage assays (DSB measurement), HR and NHEJ repair pathway assays, chromatin conformation capture, gene expression assays for BRCA1/RAD51/53BP1","journal":"Oncogene","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — functional screening with mechanistic follow-up (chromatin conformation, DNA repair pathway assays), single lab","pmids":["35017665"],"is_preprint":false},{"year":2022,"finding":"USP2 (ubiquitin-specific protease 2) physically interacts with ARID2 and reduces ARID2 protein degradation via the ubiquitination pathway; USP2 inhibits lung cancer cell invasion and migration by stabilizing ARID2 protein.","method":"IP-Mass Spectrometry, co-immunoprecipitation, immunofluorescent colocalization, CHX chase assay, ubiquitination assay, transwell/wound healing migration assay","journal":"BioMed research international","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — Co-IP and CHX chase plus ubiquitination assay, single lab, multiple orthogonal methods","pmids":["36567903"],"is_preprint":false},{"year":2016,"finding":"ARID2 represses CD44 promoter activity and protein expression in hepatocellular carcinoma cells; overexpression of ARID2 inhibits cell invasion and metastasis in vitro and tumor growth in vivo in nude mice, mediated at least in part through transcriptional repression of CD44.","method":"Luciferase reporter assay (CD44 promoter), Western blot, adenoviral ARID2 overexpression, cell migration assay, subcutaneous tumor xenograft in nude mice","journal":"Zhonghua gan zang bing za zhi","confidence":"Medium","confidence_rationale":"Tier 3 / Moderate — luciferase and Western blot supporting promoter repression, with in vivo validation, single lab","pmids":["27095763"],"is_preprint":false},{"year":2017,"finding":"HBx (HBV X protein) suppresses ARID2 transcription through ATOH1-binding elements in the ARID2 promoter region (nt-1040/nt-601); ectopic ATOH1 expression or mutation of ATOH1 binding sites partially abolishes HBx-triggered ARID2 repression, and ARID2 abrogates HBx-enhanced HCC cell migration and proliferation.","method":"Promoter deletion/luciferase assays, site-directed mutagenesis of ATOH1 binding sites, ectopic ATOH1 expression, Western blot, cell migration assays","journal":"Cancer science","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — luciferase with mutagenesis of binding sites and functional rescue experiments, single lab","pmids":["28498550"],"is_preprint":false},{"year":2020,"finding":"ARID2 haploinsufficiency is associated with enhanced RAS-MAPK (ERK1/2) activity; this is mediated through reduced IFITM1 expression, which normally interacts with caveolin-1 (CAV-1) to inhibit ERK activation. ARID2 KO in HeLa cells increases ERK1 and ERK2 phosphorylation; patient iPSCs show impaired neuronal differentiation with enhanced RAS-MAPK activity.","method":"Transient ARID2 knockout via shRNA (ERK phosphorylation), patient-derived iPSC differentiation assays, Arid2 haploinsufficient mice (CRISPR/Cas9), IFITM1/CAV-1 expression analysis","journal":"Journal of medical genetics","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — multiple model systems (cells, iPSCs, mice) with ERK phosphorylation readout, single lab","pmids":["33051312"],"is_preprint":false},{"year":2018,"finding":"NMR backbone resonance assignment of the ARID domain of human BAF200 (ARID2) was completed, providing secondary structure information; the ARID domain has the potential to bind DNA sequences with high affinity, though the exact DNA binding specificities within the PBAF context were not yet established.","method":"NMR spectroscopy (backbone 1H, 13C, 15N chemical shift assignment)","journal":"Biomolecular NMR assignments","confidence":"Low","confidence_rationale":"Tier 1 / Weak — NMR assignment only (no functional mutagenesis validation of DNA binding); single lab, preliminary structural work","pmids":["30535613"],"is_preprint":false},{"year":2024,"finding":"PBAF (defined by ARID2) occupies repressive chromatin regions co-bound by PRC2, and ARID2 loss disrupts PBAF complex formation, impairing REST transcription factor binding to its target loci. This leads to upregulation of synaptic/neuronal transcripts normally silenced by REST, a gene signature conserved in melanoma patients with ARID2 mutations.","method":"Comprehensive epigenomic profiling (ChIP-seq for SWI/SNF complexes), ARID2 knockout in melanoma cells and melanocytes, time-resolved chromatin accessibility assays, REST occupancy assays","journal":"bioRxiv","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — ChIP-seq with KO and REST occupancy validation, preprint not yet peer-reviewed","pmids":[],"is_preprint":true},{"year":2024,"finding":"ARID2 knockout in TFE3-rearranged renal cell carcinoma (TFE3-RCC) enhances ERBB3 expression; ChIP assay demonstrated that PRCC-TFE3 directly binds and upregulates ERBB3, and ARID2 KO further enhances this effect. ARID2-KO TFE3-RCC cells show increased MAPK and ERBB3 signaling activation and heightened sensitivity to ERBB3 inhibitor AZD8931.","method":"In vitro and in vivo ARID2 KO experiments, transcriptomic analysis, ChIP assay (PRCC-TFE3 binding to ERBB3), ERBB3 inhibitor sensitivity assays, migration/proliferation assays","journal":"Current issues in molecular biology","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — ChIP assay with functional KO and inhibitor validation, single lab","pmids":["39727945"],"is_preprint":false},{"year":2025,"finding":"Arid2 is required for normal B cell differentiation in vivo; Mb1-Cre-mediated deletion causes marked reduction of splenic and circulating Follicular B cells through impaired differentiation (not proliferation or survival). Arid2 loss disrupts stage-specific gene expression programs in pro-B, pre-B, and Follicular B cells, with cumulative downregulation of B cell receptor signaling pathways, and functionally impairs germinal center expansion and IgG antibody production.","method":"Conditional KO mice (Mb1-Cre, CD19-Cre), flow cytometry, RNA-seq of isolated B cell populations, immunization assays, bone marrow transplantation","journal":"bioRxiv","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — multiple Cre systems with transcriptomic and functional immune readouts, preprint pending peer review","pmids":["41256460"],"is_preprint":true}],"current_model":"ARID2 (BAF200) is a defining subunit of the PBAF SWI/SNF chromatin-remodeling complex that regulates gene-selective transcription (including interferon-responsive genes via PBAF specificity), represses oncogenic targets (Snail via DNMT1 recruitment, cyclin D1/E1 via E2F1 displacement, CD44, HSPA1A, ERBB3), facilitates homologous recombination-based DNA repair by recruiting Rad51 and XPG to damage sites, promotes ubiquitin-mediated degradation of JAK2 (through CARM1/NEDD4L-dependent chromatin regulation), is itself degraded as a pomalidomide-induced CRL4CRBN neosubstrate (requiring BRD7), can be stabilized by the deubiquitinase USP2, and is required in vivo for cardiac morphogenesis, normal hematopoiesis, and B cell differentiation."},"narrative":{"mechanistic_narrative":"ARID2 (BAF200) is a defining, gene-selectivity subunit of the PBAF SWI/SNF chromatin-remodeling complex that directs context-specific transcriptional programs in development, immunity, DNA repair, and tumor suppression [PMID:15985610]. As a PBAF specificity factor it is required for activation of interferon-responsive genes and assembles into more than one PBAF configuration, including a canonical BRG1-containing form and a distinct BRG1-independent, BAF180-containing form [PMID:15985610, PMID:28381560]. Its ARID domain has the structural potential for high-affinity DNA binding [PMID:30535613]. Beyond transcriptional activation, ARID2 acts as a transcriptional repressor of oncogenic and metastasis-promoting targets: it interacts with E2F1 to reduce E2F1/RNA Pol II occupancy of CCND1 and CCNE1 and slow G1/S progression [PMID:27351279], recruits DNMT1 to methylate and silence the Snail promoter to suppress EMT and metastasis [PMID:32071245], and represses CD44 and (in cooperation with PBAF/PRC2 chromatin) restrains additional gene programs [PMID:27095763]. ARID2 supports genome integrity through two repair pathways, enabling XPG accumulation for nucleotide excision repair and recruiting Rad51 to double-strand breaks for homologous recombination, and it co-maintains enhancer-promoter loops for BRCA1, RAD51, and 53BP1 [PMID:28238438, PMID:28381560, PMID:35017665]. In vivo, ARID2 is required for cardiac morphogenesis and coronary artery development, fetal HSC expansion and erythropoiesis, lymphoid lineage commitment, and B cell differentiation [PMID:25299188, PMID:29482581, PMID:33346030, PMID:41256460]. ARID2 protein levels are regulated by the ubiquitin system: it is a pomalidomide-induced CRL4CRBN neosubstrate whose degradation requires the PBAF subunit BRD7, and it is stabilized by the deubiquitinase USP2 [PMID:32958952, PMID:36567903]. ARID2 haploinsufficiency is associated with enhanced RAS-MAPK (ERK1/2) signaling through reduced IFITM1, with patient iPSCs showing impaired neuronal differentiation [PMID:33051312].","teleology":[{"year":2005,"claim":"Established ARID2 as a dedicated PBAF specificity subunit, answering whether PBAF and BAF complexes regulate distinct genes and which subunit confers that selectivity.","evidence":"Biochemical complex purification and in vivo transcription assays on interferon-responsive promoters","pmids":["15985610"],"confidence":"High","gaps":["Did not define which DNA sequences or cofactors ARID2 recognizes to confer specificity","Generality beyond interferon-responsive genes untested"]},{"year":2014,"claim":"Demonstrated an essential developmental requirement for ARID2 in heart and coronary vessel formation, moving it from a transcriptional factor to a physiological morphogenesis regulator.","evidence":"Conditional knockout mouse with embryonic histology and phenotyping","pmids":["25299188"],"confidence":"High","gaps":["Target genes driving the cardiac phenotype not defined","Mechanism of subepicardial-to-arterial cell fate transition unresolved"]},{"year":2016,"claim":"Defined a direct transcriptional-repressor mechanism for tumor suppression by linking ARID2 to E2F1-driven cell-cycle gene control and to CD44 repression.","evidence":"Co-IP, ChIP of E2F1/Pol II at CCND1/CCNE1, luciferase reporter, xenografts in HCC models","pmids":["27351279","27095763"],"confidence":"Medium","gaps":["Whether repression requires intact PBAF remodeling activity not tested","Direct ARID2 promoter occupancy versus indirect effects not fully separated"]},{"year":2017,"claim":"Showed ARID2 is required for two distinct DNA repair pathways, explaining how its loss promotes mutagenesis and tumorigenesis.","evidence":"CRISPR KO with XPG recruitment assays (NER) and reciprocal Co-IP plus HR/Rad51 recruitment assays; identification of two PBAF subforms","pmids":["28238438","28381560"],"confidence":"High","gaps":["Structural basis of ARID2-Rad51 and ARID2-XPG recruitment not resolved","Relative contribution of NER versus HR to tumor phenotypes unclear"]},{"year":2017,"claim":"Identified upstream transcriptional control of ARID2 itself, with HBV HBx repressing ARID2 via ATOH1 elements to promote HCC.","evidence":"Promoter deletion/luciferase, ATOH1 site mutagenesis, ectopic expression and migration assays","pmids":["28498550"],"confidence":"Medium","gaps":["Endogenous role of ATOH1 in normal ARID2 regulation untested","Single-lab promoter-level evidence"]},{"year":2018,"claim":"Provided the structural starting point for understanding ARID2-DNA recognition by assigning the ARID domain backbone.","evidence":"NMR backbone chemical shift assignment of the human BAF200 ARID domain","pmids":["30535613"],"confidence":"Low","gaps":["No functional mutagenesis validating DNA binding","DNA binding specificity within PBAF context not established"]},{"year":2018,"claim":"Extended ARID2's essential roles to the hematopoietic system, establishing a tumor-suppressor function in leukemia and a requirement for HSC expansion and erythropoiesis.","evidence":"Multiple Cre conditional knockouts, fetal liver/BM transplantation, RNA-seq, MLL-AF9 leukemia model","pmids":["29482581"],"confidence":"High","gaps":["Direct transcriptional targets in HSCs not pinpointed","Mechanism distinguishing erythroid versus stem-cell defects unclear"]},{"year":2020,"claim":"Resolved the metastasis-suppressor mechanism in HCC by tying ARID2 to DNMT1-mediated Snail promoter silencing and mapping it to the C2H2 domain.","evidence":"KO mouse HCC models, ChIP of DNMT1, bisulfite sequencing, domain mutants, metastasis assays","pmids":["32071245"],"confidence":"High","gaps":["How ARID2 physically recruits DNMT1 not structurally defined","Whether this mechanism operates outside HCC untested"]},{"year":2020,"claim":"Defined ARID2 protein-level regulation by the ubiquitin-proteasome system, identifying it as a pomalidomide-induced CRL4CRBN neosubstrate dependent on BRD7.","evidence":"Proteomics, Co-IP, BRD7 knockdown, pomalidomide degradation and MYC expression assays in myeloma","pmids":["32958952"],"confidence":"High","gaps":["Degron determinants on ARID2 not mapped","Physiological (non-drug) triggers of CRL4CRBN-mediated ARID2 turnover unknown"]},{"year":2020,"claim":"Connected ARID2 loss to anti-tumor immunity and to RAS-MAPK signaling, linking its chromatin function to STAT1/chemokine programs and IFITM1-CAV1 control of ERK.","evidence":"Melanoma KO with anti-PD-L1 treatment and CD8 infiltration; shRNA/KO with ERK phosphorylation, patient iPSC differentiation and haploinsufficient mice; lymphoid-lineage conditional KO with RNA-seq","pmids":["33333124","33051312","33346030"],"confidence":"Medium","gaps":["Direct chromatin targets bridging ARID2 to STAT1/IFITM1 not defined","Whether immune and MAPK effects share a common transcriptional node unclear"]},{"year":2021,"claim":"Identified a context-dependent driver downstream of ARID2 loss in lung adenocarcinoma, defining HSPA1A as a selective vulnerability.","evidence":"Kras GEMMs, integrated ChIP-seq/RNA-seq, HSPA1A knockdown and inhibitor in cells and animals","pmids":["34858604"],"confidence":"High","gaps":["Why HSPA1A dependency is ARID2-specific not mechanistically resolved","Direct ARID2 occupancy at HSPA1A regulatory regions not detailed"]},{"year":2022,"claim":"Uncovered a metabolic and signaling role by which ARID2 represses JAK2-STAT5-PPARgamma to limit hepatic steatosis through CARM1/NEDD4L-dependent JAK2 degradation.","evidence":"Liver-specific KO with HFD, ChIP of CARM1/H3R17me2a at NEDD4L, ubiquitination assays, JAK2 inhibitor rescue, clinical samples","pmids":["36396719"],"confidence":"High","gaps":["How ARID2 selects the NEDD4L locus for CARM1 recruitment unresolved","Relevance to non-hepatic tissues untested"]},{"year":2022,"claim":"Revealed a therapeutic synthetic-lethal interaction, showing ARID2 and BRD4 jointly sustain DSB-repair gene enhancer loops.","evidence":"Drug screen with JQ1 in ARID2-depleted HCC, DSB and HR/NHEJ assays, chromatin conformation capture, BRCA1/RAD51/53BP1 expression","pmids":["35017665"],"confidence":"Medium","gaps":["Direct cooperative binding of ARID2 and BRD4 at the loops not shown","Single-lab evidence"]},{"year":2022,"claim":"Identified USP2 as a deubiquitinase that stabilizes ARID2, complementing the CRL4CRBN degradation axis.","evidence":"IP-MS, Co-IP, immunofluorescence colocalization, CHX chase, ubiquitination and migration assays","pmids":["36567903"],"confidence":"Medium","gaps":["DUB cleavage site / ubiquitin linkage on ARID2 not mapped","Single-lab, reciprocal in vivo validation limited"]},{"year":2024,"claim":"Linked PBAF/ARID2 to repressive chromatin and REST function, and extended ARID2 tumor-suppressor logic to TFE3-RCC via ERBB3.","evidence":"ChIP-seq of SWI/SNF and REST occupancy in melanoma (preprint); ARID2 KO with PRCC-TFE3/ERBB3 ChIP and ERBB3 inhibitor sensitivity in TFE3-RCC","pmids":["39727945"],"confidence":"Medium","gaps":["Mechanism of PBAF-PRC2 co-occupancy at repressive regions not fully defined","Melanoma REST findings remain in preprint"]},{"year":2025,"claim":"Established a requirement for ARID2 in B cell differentiation and humoral immunity, refining its hematopoietic role to lineage-specific gene programs.","evidence":"Conditional KO (Mb1-Cre, CD19-Cre), flow cytometry, stage-specific RNA-seq, immunization and germinal center assays (preprint)","pmids":["41256460"],"confidence":"Medium","gaps":["Direct ARID2 targets controlling BCR-signaling genes not identified","Findings remain in preprint pending peer review"]},{"year":null,"claim":"How ARID2 selects its genomic binding sites and recruits distinct effectors (DNMT1, CARM1, Rad51, XPG, E2F1) at different loci remains unresolved at the structural and biochemical level.","evidence":"No reconstitution or structural study in the timeline maps ARID2 site selection or effector hand-off","pmids":[],"confidence":"Low","gaps":["No DNA-binding specificity defined for the ARID/C2H2 domains in PBAF context","No structure of ARID2 within an assembled PBAF complex","Rules governing activator-versus-repressor outcomes unknown"]}],"mechanism_profile":{"molecular_activity":[{"term_id":"GO:0140110","term_label":"transcription regulator activity","supporting_discovery_ids":[0,2,7,15]},{"term_id":"GO:0003677","term_label":"DNA binding","supporting_discovery_ids":[18]},{"term_id":"GO:0060090","term_label":"molecular adaptor activity","supporting_discovery_ids":[3,4,7,12]}],"localization":[{"term_id":"GO:0005634","term_label":"nucleus","supporting_discovery_ids":[0,4,7]},{"term_id":"GO:0000228","term_label":"nuclear chromosome","supporting_discovery_ids":[3,4,19]}],"pathway":[{"term_id":"R-HSA-4839726","term_label":"Chromatin organization","supporting_discovery_ids":[0,4,19]},{"term_id":"R-HSA-74160","term_label":"Gene expression (Transcription)","supporting_discovery_ids":[0,2,7,11]},{"term_id":"R-HSA-73894","term_label":"DNA Repair","supporting_discovery_ids":[3,4,13]},{"term_id":"R-HSA-1640170","term_label":"Cell Cycle","supporting_discovery_ids":[2]},{"term_id":"R-HSA-168256","term_label":"Immune System","supporting_discovery_ids":[0,9,21]},{"term_id":"R-HSA-1266738","term_label":"Developmental Biology","supporting_discovery_ids":[1,5,17,21]},{"term_id":"R-HSA-392499","term_label":"Metabolism of proteins","supporting_discovery_ids":[8,12,14]}],"complexes":["PBAF SWI/SNF complex"],"partners":["E2F1","DNMT1","RAD51","BRD7","USP2","CARM1","BRD4"],"other_free_text":[]}},"prefetch_data":{"uniprot":{"accession":"Q68CP9","full_name":"AT-rich interactive domain-containing protein 2","aliases":["BRG1-associated factor 200","BAF200","Zinc finger protein with activation potential","Zipzap/p200"],"length_aa":1835,"mass_kda":197.4,"function":"Involved in transcriptional activation and repression of select genes by chromatin remodeling (alteration of DNA-nucleosome topology). Required for the stability of the SWI/SNF chromatin remodeling complex SWI/SNF-B (PBAF). May be involved in targeting the complex to different genes. May be involved in regulating transcriptional activation of cardiac genes","subcellular_location":"Nucleus","url":"https://www.uniprot.org/uniprotkb/Q68CP9/entry"},"depmap":{"release":"DepMap","has_data":true,"is_common_essential":false,"resolved_as":"","url":"https://depmap.org/portal/gene/ARID2","classification":"Not Classified","n_dependent_lines":472,"n_total_lines":1208,"dependency_fraction":0.39072847682119205},"opencell":{"profiled":false,"resolved_as":"","ensg_id":"","cell_line_id":"","localizations":[],"interactors":[{"gene":"SMARCA4","stoichiometry":4.0},{"gene":"HIST2H2BE","stoichiometry":0.2}],"url":"https://opencell.sf.czbiohub.org/search/ARID2","total_profiled":1310},"omim":[{"mim_id":"617808","title":"COFFIN-SIRIS SYNDROME 6; CSS6","url":"https://www.omim.org/entry/617808"},{"mim_id":"611549","title":"SODIUM LEAK CHANNEL, NONSELECTIVE; NALCN","url":"https://www.omim.org/entry/611549"},{"mim_id":"610999","title":"ENHANCER OF POLYCOMB HOMOLOG 1; EPC1","url":"https://www.omim.org/entry/610999"},{"mim_id":"609539","title":"AT-RICH INTERACTION DOMAIN-CONTAINING PROTEIN 2; ARID2","url":"https://www.omim.org/entry/609539"},{"mim_id":"607585","title":"ATM SERINE/THREONINE KINASE; ATM","url":"https://www.omim.org/entry/607585"}],"hpa":{"profiled":true,"resolved_as":"","reliability":"Supported","locations":[{"location":"Nucleoplasm","reliability":"Supported"}],"tissue_specificity":"Low tissue specificity","tissue_distribution":"Detected in all","driving_tissues":[],"url":"https://www.proteinatlas.org/search/ARID2"},"hgnc":{"alias_symbol":["KIAA1557","DKFZp686G052","FLJ30619","BAF200","SMARCF3","ZIPZAP","p200"],"prev_symbol":[]},"alphafold":{"accession":"Q68CP9","domains":[{"cath_id":"1.10.150.60","chopping":"23-112","consensus_level":"medium","plddt":82.4034,"start":23,"end":112},{"cath_id":"1.25.10.10","chopping":"156-253_270-396","consensus_level":"medium","plddt":88.5461,"start":156,"end":396},{"cath_id":"1.10.10.10","chopping":"520-609","consensus_level":"high","plddt":84.1876,"start":520,"end":609},{"cath_id":"-","chopping":"1627-1700","consensus_level":"medium","plddt":84.4736,"start":1627,"end":1700}],"viewer_url":"https://alphafold.ebi.ac.uk/entry/Q68CP9","model_url":"https://alphafold.ebi.ac.uk/files/AF-Q68CP9-F1-model_v6.cif","pae_url":"https://alphafold.ebi.ac.uk/files/AF-Q68CP9-F1-predicted_aligned_error_v6.png","plddt_mean":51.16},"mouse_models":{"mgi_url":"https://www.informatics.jax.org/marker/summary?nomen=ARID2","jax_strain_url":"https://www.jax.org/strain/search?query=ARID2"},"sequence":{"accession":"Q68CP9","fasta_url":"https://rest.uniprot.org/uniprotkb/Q68CP9.fasta","uniprot_url":"https://www.uniprot.org/uniprotkb/Q68CP9/entry","alphafold_viewer_url":"https://alphafold.ebi.ac.uk/entry/Q68CP9"}},"corpus_meta":[{"pmid":"21822264","id":"PMC_21822264","title":"Inactivating mutations of the chromatin remodeling gene ARID2 in hepatocellular carcinoma.","date":"2011","source":"Nature genetics","url":"https://pubmed.ncbi.nlm.nih.gov/21822264","citation_count":338,"is_preprint":false},{"pmid":"15985610","id":"PMC_15985610","title":"PBAF chromatin-remodeling complex requires a novel specificity subunit, BAF200, to regulate expression of selective interferon-responsive genes.","date":"2005","source":"Genes & development","url":"https://pubmed.ncbi.nlm.nih.gov/15985610","citation_count":191,"is_preprint":false},{"pmid":"25743111","id":"PMC_25743111","title":"Long Noncoding RNA Arid2-IR Is a Novel Therapeutic Target for Renal Inflammation.","date":"2015","source":"Molecular therapy : the journal of the American Society of Gene Therapy","url":"https://pubmed.ncbi.nlm.nih.gov/25743111","citation_count":117,"is_preprint":false},{"pmid":"24382590","id":"PMC_24382590","title":"Exome sequencing reveals frequent inactivating mutations in ARID1A, ARID1B, ARID2 and ARID4A in microsatellite unstable colorectal cancer.","date":"2014","source":"International journal of cancer","url":"https://pubmed.ncbi.nlm.nih.gov/24382590","citation_count":101,"is_preprint":false},{"pmid":"32071245","id":"PMC_32071245","title":"Chromatin remodeling factor ARID2 suppresses hepatocellular carcinoma metastasis via DNMT1-Snail axis.","date":"2020","source":"Proceedings of the National Academy of Sciences of the United States of America","url":"https://pubmed.ncbi.nlm.nih.gov/32071245","citation_count":89,"is_preprint":false},{"pmid":"32958952","id":"PMC_32958952","title":"ARID2 is a pomalidomide-dependent CRL4CRBN substrate in multiple myeloma cells.","date":"2020","source":"Nature chemical biology","url":"https://pubmed.ncbi.nlm.nih.gov/32958952","citation_count":75,"is_preprint":false},{"pmid":"31918270","id":"PMC_31918270","title":"MiR-155-5p promotes oral cancer progression by targeting chromatin remodeling gene ARID2.","date":"2019","source":"Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie","url":"https://pubmed.ncbi.nlm.nih.gov/31918270","citation_count":72,"is_preprint":false},{"pmid":"23047306","id":"PMC_23047306","title":"Recurrent inactivating mutations of ARID2 in non-small cell lung carcinoma.","date":"2012","source":"International journal of cancer","url":"https://pubmed.ncbi.nlm.nih.gov/23047306","citation_count":65,"is_preprint":false},{"pmid":"34512623","id":"PMC_34512623","title":"ARID1A, ARID1B, and ARID2 Mutations Serve as Potential Biomarkers for Immune Checkpoint Blockade in Patients With Non-Small Cell Lung Cancer.","date":"2021","source":"Frontiers in immunology","url":"https://pubmed.ncbi.nlm.nih.gov/34512623","citation_count":58,"is_preprint":false},{"pmid":"28238438","id":"PMC_28238438","title":"ARID2 modulates DNA damage response in human hepatocellular carcinoma cells.","date":"2017","source":"Journal of hepatology","url":"https://pubmed.ncbi.nlm.nih.gov/28238438","citation_count":55,"is_preprint":false},{"pmid":"28124119","id":"PMC_28124119","title":"Heterozygosity for ARID2 loss-of-function mutations in individuals with a Coffin-Siris syndrome-like phenotype.","date":"2017","source":"Human genetics","url":"https://pubmed.ncbi.nlm.nih.gov/28124119","citation_count":54,"is_preprint":false},{"pmid":"26238514","id":"PMC_26238514","title":"Mutations in ARID2 are associated with intellectual disabilities.","date":"2015","source":"Neurogenetics","url":"https://pubmed.ncbi.nlm.nih.gov/26238514","citation_count":53,"is_preprint":false},{"pmid":"27035278","id":"PMC_27035278","title":"MicroRNA-155 promotes tumor growth of human hepatocellular carcinoma by targeting ARID2.","date":"2016","source":"International journal of oncology","url":"https://pubmed.ncbi.nlm.nih.gov/27035278","citation_count":50,"is_preprint":false},{"pmid":"22095441","id":"PMC_22095441","title":"ARID2: a new tumor suppressor gene in hepatocellular carcinoma.","date":"2011","source":"Oncotarget","url":"https://pubmed.ncbi.nlm.nih.gov/22095441","citation_count":47,"is_preprint":false},{"pmid":"27351279","id":"PMC_27351279","title":"Chromatin remodeling gene ARID2 targets cyclin D1 and cyclin E1 to suppress hepatoma cell progression.","date":"2016","source":"Oncotarget","url":"https://pubmed.ncbi.nlm.nih.gov/27351279","citation_count":36,"is_preprint":false},{"pmid":"33742126","id":"PMC_33742126","title":"ARID2 deficiency promotes tumor progression and is associated with higher sensitivity to chemotherapy in lung cancer.","date":"2021","source":"Oncogene","url":"https://pubmed.ncbi.nlm.nih.gov/33742126","citation_count":33,"is_preprint":false},{"pmid":"25299188","id":"PMC_25299188","title":"BAF200 is required for heart morphogenesis and coronary artery development.","date":"2014","source":"PloS one","url":"https://pubmed.ncbi.nlm.nih.gov/25299188","citation_count":31,"is_preprint":false},{"pmid":"29482581","id":"PMC_29482581","title":"The chromatin remodeling subunit Baf200 promotes normal hematopoiesis and inhibits leukemogenesis.","date":"2018","source":"Journal of hematology & oncology","url":"https://pubmed.ncbi.nlm.nih.gov/29482581","citation_count":31,"is_preprint":false},{"pmid":"33333124","id":"PMC_33333124","title":"ARID2 Deficiency Correlates with the Response to Immune Checkpoint Blockade in Melanoma.","date":"2020","source":"The Journal of investigative dermatology","url":"https://pubmed.ncbi.nlm.nih.gov/33333124","citation_count":31,"is_preprint":false},{"pmid":"28381560","id":"PMC_28381560","title":"The chromatin-remodeling subunit Baf200 promotes homology-directed DNA repair and regulates distinct chromatin-remodeling complexes.","date":"2017","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/28381560","citation_count":30,"is_preprint":false},{"pmid":"26637902","id":"PMC_26637902","title":"Loss of ARID1A, ARID1B, and ARID2 Expression During Progression of Gastric Cancer.","date":"2015","source":"Anticancer research","url":"https://pubmed.ncbi.nlm.nih.gov/26637902","citation_count":29,"is_preprint":false},{"pmid":"26169693","id":"PMC_26169693","title":"miR-208-3p promotes hepatocellular carcinoma cell proliferation and invasion through regulating ARID2 expression.","date":"2015","source":"Experimental cell research","url":"https://pubmed.ncbi.nlm.nih.gov/26169693","citation_count":28,"is_preprint":false},{"pmid":"33262464","id":"PMC_33262464","title":"Exome sequencing identifies ARID2 as a novel tumor suppressor in early-onset sporadic rectal cancer.","date":"2020","source":"Oncogene","url":"https://pubmed.ncbi.nlm.nih.gov/33262464","citation_count":27,"is_preprint":false},{"pmid":"30462533","id":"PMC_30462533","title":"Early growth response protein-1 upregulates long noncoding RNA Arid2-IR to promote extracellular matrix production in diabetic kidney disease.","date":"2018","source":"American journal of physiology. Cell physiology","url":"https://pubmed.ncbi.nlm.nih.gov/30462533","citation_count":25,"is_preprint":false},{"pmid":"34858604","id":"PMC_34858604","title":"Targeting HSPA1A in ARID2-deficient lung adenocarcinoma.","date":"2021","source":"National science review","url":"https://pubmed.ncbi.nlm.nih.gov/34858604","citation_count":21,"is_preprint":false},{"pmid":"32977645","id":"PMC_32977645","title":"ARID2 Chromatin Remodeler in Hepatocellular Carcinoma.","date":"2020","source":"Cells","url":"https://pubmed.ncbi.nlm.nih.gov/32977645","citation_count":20,"is_preprint":false},{"pmid":"31075894","id":"PMC_31075894","title":"Human Hepatitis B Virus Core Protein Inhibits IFNα-Induced IFITM1 Expression by Interacting with BAF200.","date":"2019","source":"Viruses","url":"https://pubmed.ncbi.nlm.nih.gov/31075894","citation_count":18,"is_preprint":false},{"pmid":"28498550","id":"PMC_28498550","title":"HBx protein-mediated ATOH1 downregulation suppresses ARID2 expression and promotes hepatocellular carcinoma.","date":"2017","source":"Cancer science","url":"https://pubmed.ncbi.nlm.nih.gov/28498550","citation_count":18,"is_preprint":false},{"pmid":"33090288","id":"PMC_33090288","title":"Arid2-IR promotes NF-κB-mediated renal inflammation by targeting NLRC5 transcription.","date":"2020","source":"Cellular and molecular life sciences : CMLS","url":"https://pubmed.ncbi.nlm.nih.gov/33090288","citation_count":18,"is_preprint":false},{"pmid":"33346030","id":"PMC_33346030","title":"Arid2 regulates hematopoietic stem cell differentiation in normal hematopoiesis.","date":"2020","source":"Experimental hematology","url":"https://pubmed.ncbi.nlm.nih.gov/33346030","citation_count":17,"is_preprint":false},{"pmid":"35017665","id":"PMC_35017665","title":"BRD4 inhibition induces synthetic lethality in ARID2-deficient hepatocellular carcinoma by increasing DNA damage.","date":"2022","source":"Oncogene","url":"https://pubmed.ncbi.nlm.nih.gov/35017665","citation_count":17,"is_preprint":false},{"pmid":"36396719","id":"PMC_36396719","title":"ARID2 mitigates hepatic steatosis via promoting the ubiquitination of JAK2.","date":"2022","source":"Cell death and differentiation","url":"https://pubmed.ncbi.nlm.nih.gov/36396719","citation_count":16,"is_preprint":false},{"pmid":"28944851","id":"PMC_28944851","title":"microRNA‑96 regulates the proliferation of nucleus pulposus cells by targeting ARID2/AKT signaling.","date":"2017","source":"Molecular medicine reports","url":"https://pubmed.ncbi.nlm.nih.gov/28944851","citation_count":16,"is_preprint":false},{"pmid":"28884947","id":"PMC_28884947","title":"Confirmation of an ARID2 defect in SWI/SNF-related intellectual disability.","date":"2017","source":"American journal of medical genetics. Part A","url":"https://pubmed.ncbi.nlm.nih.gov/28884947","citation_count":16,"is_preprint":false},{"pmid":"33786634","id":"PMC_33786634","title":"CREB1 acts via the miR‑922/ARID2 axis to enhance malignant behavior of liver cancer cells.","date":"2021","source":"Oncology reports","url":"https://pubmed.ncbi.nlm.nih.gov/33786634","citation_count":14,"is_preprint":false},{"pmid":"29698805","id":"PMC_29698805","title":"Extending the clinical and genetic spectrum of ARID2 related intellectual disability. A case series of 7 patients.","date":"2018","source":"European journal of medical genetics","url":"https://pubmed.ncbi.nlm.nih.gov/29698805","citation_count":13,"is_preprint":false},{"pmid":"30838730","id":"PMC_30838730","title":"Patient with anomalous skin pigmentation expands the phenotype of ARID2 loss-of-function disorder, a SWI/SNF-related intellectual disability.","date":"2019","source":"American journal of medical genetics. Part A","url":"https://pubmed.ncbi.nlm.nih.gov/30838730","citation_count":13,"is_preprint":false},{"pmid":"36567903","id":"PMC_36567903","title":"USP2 Inhibits Lung Cancer Pathogenesis by Reducing ARID2 Protein Degradation via Ubiquitination.","date":"2022","source":"BioMed research international","url":"https://pubmed.ncbi.nlm.nih.gov/36567903","citation_count":12,"is_preprint":false},{"pmid":"35144623","id":"PMC_35144623","title":"Concomitant novel ALK-SSH2, EML4-ALK and ARID2-ALK, EML4-ALK double-fusion variants and confer sensitivity to crizotinib in two lung adenocarcinoma patients, respectively.","date":"2022","source":"Diagnostic pathology","url":"https://pubmed.ncbi.nlm.nih.gov/35144623","citation_count":11,"is_preprint":false},{"pmid":"33051312","id":"PMC_33051312","title":"Association between ARID2 and RAS-MAPK pathway in intellectual disability and short stature.","date":"2020","source":"Journal of medical genetics","url":"https://pubmed.ncbi.nlm.nih.gov/33051312","citation_count":9,"is_preprint":false},{"pmid":"36315994","id":"PMC_36315994","title":"SIS3 Alleviates Cisplatin-Induced Acute Kidney Injury by Regulating the LncRNA Arid2-IR-Transferrin Receptor Pathway.","date":"2022","source":"Kidney & blood pressure research","url":"https://pubmed.ncbi.nlm.nih.gov/36315994","citation_count":9,"is_preprint":false},{"pmid":"38341515","id":"PMC_38341515","title":"ARID2 mutations may relay a distinct subset of cutaneous melanoma patients with different outcomes.","date":"2024","source":"Scientific reports","url":"https://pubmed.ncbi.nlm.nih.gov/38341515","citation_count":8,"is_preprint":false},{"pmid":"35813374","id":"PMC_35813374","title":"ARID2, a Rare Cause of Coffin-Siris Syndrome: A Clinical Description of Two Cases.","date":"2022","source":"Frontiers in pediatrics","url":"https://pubmed.ncbi.nlm.nih.gov/35813374","citation_count":8,"is_preprint":false},{"pmid":"31912402","id":"PMC_31912402","title":"Long non-coding RNA Arid2-IR affects advanced glycation end products-induced human retinal endothelial cell injury by binding to Smad3.","date":"2020","source":"International ophthalmology","url":"https://pubmed.ncbi.nlm.nih.gov/31912402","citation_count":7,"is_preprint":false},{"pmid":"36756859","id":"PMC_36756859","title":"ARID2, a rare cause of Coffin-Siris syndrome: A novel microdeletion at 12q12q13.11 causing severe short stature and literature review.","date":"2023","source":"American journal of medical genetics. Part A","url":"https://pubmed.ncbi.nlm.nih.gov/36756859","citation_count":7,"is_preprint":false},{"pmid":"38243407","id":"PMC_38243407","title":"ARID2, a milder cause of Coffin-Siris Syndrome? Broadening the phenotype with 17 additional individuals.","date":"2024","source":"American journal of medical genetics. Part A","url":"https://pubmed.ncbi.nlm.nih.gov/38243407","citation_count":6,"is_preprint":false},{"pmid":"36530029","id":"PMC_36530029","title":"miR-29a-5p regulates the malignant biological process of liver cancer cells through ARID2 regulation of EMT.","date":"2023","source":"Advances in clinical and experimental medicine : official organ Wroclaw Medical University","url":"https://pubmed.ncbi.nlm.nih.gov/36530029","citation_count":5,"is_preprint":false},{"pmid":"26634163","id":"PMC_26634163","title":"Clinicopathological and Targeted Exome Gene Features of a Patient with Metastatic Acinic Cell Carcinoma of the Parotid Gland Harboring an ARID2 Nonsense Mutation and CDKN2A/B Deletion.","date":"2015","source":"Case reports in oncological medicine","url":"https://pubmed.ncbi.nlm.nih.gov/26634163","citation_count":5,"is_preprint":false},{"pmid":"36074605","id":"PMC_36074605","title":"Arid2-IR downregulates miR-132-3p through methylation to promote LPS-induced ALI in pneumonia.","date":"2022","source":"Inhalation toxicology","url":"https://pubmed.ncbi.nlm.nih.gov/36074605","citation_count":4,"is_preprint":false},{"pmid":"40044822","id":"PMC_40044822","title":"ARID2-related disorder: further delineation of the clinical phenotype of 27 novel individuals and description of an epigenetic signature.","date":"2025","source":"European journal of human genetics : EJHG","url":"https://pubmed.ncbi.nlm.nih.gov/40044822","citation_count":4,"is_preprint":false},{"pmid":"29072391","id":"PMC_29072391","title":"Analysis of ARID2 Gene Mutation in Oral Squamous Cell Carcinoma.","date":"2017","source":"Asian Pacific journal of cancer prevention : APJCP","url":"https://pubmed.ncbi.nlm.nih.gov/29072391","citation_count":4,"is_preprint":false},{"pmid":"37664441","id":"PMC_37664441","title":"Early progression and transformation of a splenic diffuse red pulp small B-cell lymphoma with NOTCH1, ARID2, CREBBP, and TNFRSF14 gene mutations.","date":"2023","source":"Leukemia research reports","url":"https://pubmed.ncbi.nlm.nih.gov/37664441","citation_count":3,"is_preprint":false},{"pmid":"39727945","id":"PMC_39727945","title":"ARID2 Deficiency Enhances Tumor Progression via ERBB3 Signaling in TFE3-Rearranged Renal Cell Carcinoma.","date":"2024","source":"Current issues in molecular biology","url":"https://pubmed.ncbi.nlm.nih.gov/39727945","citation_count":2,"is_preprint":false},{"pmid":"30535613","id":"PMC_30535613","title":"Sequential backbone resonance assignment of AT-rich interaction domain of human BAF200.","date":"2018","source":"Biomolecular NMR assignments","url":"https://pubmed.ncbi.nlm.nih.gov/30535613","citation_count":2,"is_preprint":false},{"pmid":"27095763","id":"PMC_27095763","title":"[The regulation of CD44 expression by new tumor suppressor gene Arid2 and the influence of Arid2 on the invasion and metastasis in hepatocellular carcinoma cells].","date":"2016","source":"Zhonghua gan zang bing za zhi = Zhonghua ganzangbing zazhi = Chinese journal of hepatology","url":"https://pubmed.ncbi.nlm.nih.gov/27095763","citation_count":1,"is_preprint":false},{"pmid":"41256460","id":"PMC_41256460","title":"Arid2 promotes Follicular B-cell differentiation and antibody responses in vivo.","date":"2025","source":"bioRxiv : the preprint server for biology","url":"https://pubmed.ncbi.nlm.nih.gov/41256460","citation_count":0,"is_preprint":false},{"pmid":"39054516","id":"PMC_39054516","title":"Revealing the clinical impact of MTOR and ARID2 gene mutations on MALT lymphoma of the alimentary canal using targeted sequencing.","date":"2024","source":"Diagnostic pathology","url":"https://pubmed.ncbi.nlm.nih.gov/39054516","citation_count":0,"is_preprint":false},{"pmid":"38721575","id":"PMC_38721575","title":"Frameshift Variant in ARID2 in a Chilean Individual with Coffin-Siris Syndrome Phenotype.","date":"2021","source":"Journal of pediatric genetics","url":"https://pubmed.ncbi.nlm.nih.gov/38721575","citation_count":0,"is_preprint":false},{"pmid":"41764760","id":"PMC_41764760","title":"Targeting the STK39/ARID2 Axis to Inhibit NF-κB Signaling: A Novel Pathway for Mesenchymal Stem Cell Osteogenic Differentiation in Osteoporosis Management.","date":"2026","source":"Journal of musculoskeletal & neuronal interactions","url":"https://pubmed.ncbi.nlm.nih.gov/41764760","citation_count":0,"is_preprint":false},{"pmid":"41765118","id":"PMC_41765118","title":"A novel variant in ARID2 causes Coffin-Siris syndrome 6 with liver cirrhosis.","date":"2026","source":"Gene","url":"https://pubmed.ncbi.nlm.nih.gov/41765118","citation_count":0,"is_preprint":false},{"pmid":"42232299","id":"PMC_42232299","title":"A guide to selecting high-performing antibodies for ARID2 (UniProt ID: Q68CP9) for use in western blot, immunoprecipitation, and immunofluorescence.","date":"2026","source":"F1000Research","url":"https://pubmed.ncbi.nlm.nih.gov/42232299","citation_count":0,"is_preprint":false},{"pmid":"42028735","id":"PMC_42028735","title":"[Retracted] MicroRNA‑155 promotes tumor growth of human hepatocellular carcinoma by targeting ARID2.","date":"2026","source":"International journal of oncology","url":"https://pubmed.ncbi.nlm.nih.gov/42028735","citation_count":0,"is_preprint":false},{"pmid":null,"id":"bio_10.1101_2025.10.01.678812","title":"Arid2 promotes Follicular B-cell differentiation and antibody responses  <i>in vivo</i>","date":"2025-10-01","source":"bioRxiv","url":"https://doi.org/10.1101/2025.10.01.678812","citation_count":0,"is_preprint":true},{"pmid":null,"id":"bio_10.1101_2024.08.23.609212","title":"The SWI/SNF PBAF complex facilitates REST occupancy at repressive chromatin","date":"2024-08-23","source":"bioRxiv","url":"https://doi.org/10.1101/2024.08.23.609212","citation_count":0,"is_preprint":true},{"pmid":null,"id":"bio_10.1101_2024.07.23.604673","title":"Genetic evolution of keratinocytes to cutaneous squamous cell carcinoma","date":"2024-07-24","source":"bioRxiv","url":"https://doi.org/10.1101/2024.07.23.604673","citation_count":0,"is_preprint":true}],"cost":{"stage1":{"model":"claude-sonnet-4-6","input_tokens":32780,"output_tokens":5879,"usd":0.093262,"stage1_stop_reason":"end_turn"},"stage2":{"model":"claude-opus-4-8","input_tokens":14349,"output_tokens":5267,"usd":0.10171,"stage2_stop_reason":"end_turn"},"total_usd":0.194972,"stage1_batch_id":"msgbatch_0179Z2pxRYBsXi2xADneafRw","stage2_batch_id":"msgbatch_01LaY9ZaVdgjWArcZo9eqQE5","note":"batch pricing = 50% of standard"},"stage1_raw":"```json\n{\n  \"discoveries\": [\n    {\n      \"year\": 2005,\n      \"finding\": \"ARID2 (BAF200) is a specificity subunit of the PBAF chromatin-remodeling complex (SWI/SNF family) required for selective transcriptional activation of interferon-responsive genes; PBAF and BAF regulate expression of distinct gene sets, and this selectivity requires BAF200 but not the previously described PBAF-specificity subunit BAF180.\",\n      \"method\": \"Biochemical complex purification, in vivo gene expression studies comparing PBAF vs BAF complex activity on interferon-responsive gene promoters\",\n      \"journal\": \"Genes & development\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — multiple orthogonal methods (complex purification, in vivo transcription assays), foundational study identifying ARID2 as PBAF subunit with specific function\",\n      \"pmids\": [\"15985610\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2014,\n      \"finding\": \"BAF200 (ARID2) is required for heart morphogenesis and coronary artery development in vivo; BAF200 mutant mice are embryonic lethal with thin myocardium, ventricular septum defect, common atrioventricular valve, double outlet right ventricle, and reduced intramyocardial coronary arteries, indicating a role in migration and differentiation of subepicardial venous cells into arterial endothelial cells.\",\n      \"method\": \"BAF200 mutant mouse generation (conditional knockout), histology, embryonic phenotype analysis\",\n      \"journal\": \"PloS one\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — clean in vivo knockout with specific and reproducible cardiac phenotypic readout\",\n      \"pmids\": [\"25299188\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2016,\n      \"finding\": \"ARID2 suppresses hepatoma cell proliferation and tumor growth by physically interacting with E2F1 and decreasing E2F1/RNA Pol II binding to the promoters of CCND1 (cyclin D1) and CCNE1 (cyclin E1), thereby repressing their transcription and retarding G1/S cell cycle progression.\",\n      \"method\": \"Co-immunoprecipitation (physical interaction with E2F1), ChIP assay (E2F1/RNA Pol II binding to CCND1/CCNE1 promoters), gain/loss-of-function proliferation assays, mouse xenograft tumor growth\",\n      \"journal\": \"Oncotarget\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — Co-IP plus ChIP establishing promoter occupancy mechanism, single lab with two orthogonal methods\",\n      \"pmids\": [\"27351279\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2017,\n      \"finding\": \"ARID2 is required for nucleotide excision repair (NER): ARID2 knockout in HCC cells attenuates NER at UV-induced and chemically induced DNA damage sites because XPG (xeroderma pigmentosum group G protein) cannot accumulate without ARID2, resulting in susceptibility to carcinogens and increased somatic mutation burden.\",\n      \"method\": \"CRISPR/Cas9 ARID2 knockout, gene expression profiling, UV irradiation sensitivity assays, XPG recruitment assay, large-scale public dataset validation\",\n      \"journal\": \"Journal of hepatology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — CRISPR KO with mechanistic follow-up (XPG recruitment) and validation in public datasets; multiple orthogonal approaches\",\n      \"pmids\": [\"28238438\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2017,\n      \"finding\": \"Baf200 (ARID2) facilitates homologous recombination-dependent DNA double-strand break (DSB) repair by recruiting Rad51 to DSBs; Baf200 and Rad51 are present in the same complex mediated by C-terminal sequences in both proteins. Baf200 also forms at least two distinct PBAF complexes: one canonical form containing BRG1, and another containing Baf180 but not BRG1.\",\n      \"method\": \"Cytological and biochemical approaches (co-immunoprecipitation, homology-directed repair assays, Rad51 recruitment assays, cell survival after DNA damage)\",\n      \"journal\": \"The Journal of biological chemistry\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — reciprocal Co-IP, functional HR assay, and identification of two distinct complexes in a single rigorous study\",\n      \"pmids\": [\"28381560\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2018,\n      \"finding\": \"Baf200 (ARID2) is required for fetal hematopoietic stem cell (HSC) expansion and erythropoiesis; Tie2-Cre-mediated loss causes perinatal death from defective erythropoiesis; conditional knockout HSCs show impaired long-term reconstitution potential in transplantation assays; loss of Baf200 in MLL-AF9-driven leukemia accelerates tumor burden, indicating a tumor suppressor role in hematopoiesis.\",\n      \"method\": \"Tie2-Cre, Vav-iCre, Mx1-Cre conditional knockouts, fetal liver/bone marrow transplantation, RNA-seq, cell cycle/apoptosis assays, MLL-AF9 leukemia mouse model\",\n      \"journal\": \"Journal of hematology & oncology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — multiple Cre systems and transplantation assays with specific hematopoietic phenotypes, multiple orthogonal methods\",\n      \"pmids\": [\"29482581\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2019,\n      \"finding\": \"HBV core protein (HBc) physically interacts with BAF200 (ARID2) C-terminus, disrupting PBAF complex stability; this interaction suppresses IFITM1 transcription, where basal IFITM1 expression depends on BAF200 rather than the JAK-STAT1 pathway. HBc-mediated PBAF disruption thus inhibits IFNα-induced IFITM1 expression, contributing to HBV immune evasion.\",\n      \"method\": \"Yeast two-hybrid (initial identification), co-immunoprecipitation in 293T, HepG2, HepG2-NTCP cells, IFITM1 luciferase/expression assays, HBV replication assays\",\n      \"journal\": \"Viruses\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — reciprocal Co-IP in multiple cell lines, functional validation of IFITM1 suppression, single lab\",\n      \"pmids\": [\"31075894\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2020,\n      \"finding\": \"ARID2 suppresses HCC metastasis and epithelial-mesenchymal transition (EMT) by recruiting DNMT1 to the Snail promoter, increasing promoter methylation and inhibiting Snail transcription. ARID2 mutants with disrupted C2H2 domain lose this metastasis suppressor function.\",\n      \"method\": \"ARID2 KO in HCC mouse models, in vitro migration/invasion assays, in vivo metastasis assays, ChIP assay (DNMT1 recruitment to Snail promoter), bisulfite sequencing (promoter methylation), domain mutant functional analysis\",\n      \"journal\": \"Proceedings of the National Academy of Sciences of the United States of America\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — multiple orthogonal methods (KO mouse models, ChIP, bisulfite sequencing, domain mutagenesis) in a single rigorous study\",\n      \"pmids\": [\"32071245\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2020,\n      \"finding\": \"ARID2 is a pomalidomide-induced neosubstrate of the CRL4CRBN E3 ubiquitin ligase complex; pomalidomide induces ARID2 degradation in multiple myeloma cells, and BRD7 (another PBAF subunit) is critical for this pomalidomide-induced ARID2 degradation. ARID2 regulates transcription of pomalidomide target genes including MYC.\",\n      \"method\": \"Proteomics, co-immunoprecipitation, BRD7 knockdown, pomalidomide treatment with protein degradation assays, MYC expression assays, proliferation assays\",\n      \"journal\": \"Nature chemical biology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — multiple orthogonal methods (proteomics, Co-IP, functional degradation assays, BRD7 dependency), rigorous mechanistic characterization\",\n      \"pmids\": [\"32958952\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2020,\n      \"finding\": \"ARID2 deficiency leads to STAT1 upregulation, which subsequently causes increased expression of T-cell-attracting chemokines CXCL9, CXCL10, and CCL5, sensitizing melanoma to anti-PD-L1 immune checkpoint inhibitors with increased CD8+ T cell infiltration.\",\n      \"method\": \"ARID2 knockout in melanoma cells, in vivo anti-PD-L1 treatment, flow cytometry (CD8+ T cell infiltration), gene expression analysis\",\n      \"journal\": \"The Journal of investigative dermatology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — in vivo KO with functional immune readout and mechanistic gene expression link, single lab\",\n      \"pmids\": [\"33333124\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2020,\n      \"finding\": \"Loss of Arid2 in HSCs impairs lymphoid lineage differentiation in a cell-autonomous manner; Arid2 knockout enriches myeloid-biased MPP signatures while depleting lymphoid-biased MPPs, and upregulates inflammatory pathways including TLR receptors and downstream signaling genes.\",\n      \"method\": \"Conditional Arid2 knockout mouse, bone marrow transplantation, RNA-seq, in vitro lymphocyte growth assays with LPS stimulation\",\n      \"journal\": \"Experimental hematology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — conditional KO with transplantation and RNA-seq, single lab\",\n      \"pmids\": [\"33346030\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2021,\n      \"finding\": \"ARID2 deficiency promotes lung adenocarcinoma progression; through ChIP-seq and RNA-seq integration, Hspa1a was identified as upregulated by Arid2 loss, and HSPA1A knockdown specifically inhibits malignant progression of Arid2-deficient but not Arid2-wild-type lung cancers in cell lines and animal models.\",\n      \"method\": \"Kras-based genetically engineered mouse models, ARID2 KO, ChIP-seq, RNA-seq, HSPA1A knockdown, HSPA1A inhibitor treatment, in vivo tumor models\",\n      \"journal\": \"National science review\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — integrative ChIP-seq/RNA-seq with functional KO and inhibitor validation in both cells and animal models\",\n      \"pmids\": [\"34858604\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2022,\n      \"finding\": \"ARID2 mitigates hepatic steatosis by repressing JAK2-STAT5-PPARγ signaling; ARID2 promotes ubiquitination and degradation of JAK2 via NEDD4L (an E3 ligase for JAK2). Mechanistically, ARID2 recruits CARM1 to increase H3R17me2a at the NEDD4L promoter, activating NEDD4L transcription.\",\n      \"method\": \"Liver-specific Arid2 KO mouse (including HFD model), ChIP assay (CARM1 and H3R17me2a at NEDD4L promoter), ubiquitination assays, JAK2 inhibitor (Fedratinib) rescue, co-immunoprecipitation\",\n      \"journal\": \"Cell death and differentiation\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — in vivo KO with ChIP, ubiquitination assay, inhibitor rescue, and clinical sample validation; multiple orthogonal methods in single study\",\n      \"pmids\": [\"36396719\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2022,\n      \"finding\": \"BRD4 inhibition (JQ1) induces synthetic lethality in ARID2-deficient HCC cells by exacerbating DNA double-strand breaks; both ARID2 and BRD4 synergistically maintain transcriptional enhancer-promoter loops for BRCA1, RAD51, and 53BP1, and loss of both impairs their expression, preventing DSB repair.\",\n      \"method\": \"High-throughput drug screening, JQ1 treatment in ARID2-depleted HCC cells, DNA damage assays (DSB measurement), HR and NHEJ repair pathway assays, chromatin conformation capture, gene expression assays for BRCA1/RAD51/53BP1\",\n      \"journal\": \"Oncogene\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — functional screening with mechanistic follow-up (chromatin conformation, DNA repair pathway assays), single lab\",\n      \"pmids\": [\"35017665\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2022,\n      \"finding\": \"USP2 (ubiquitin-specific protease 2) physically interacts with ARID2 and reduces ARID2 protein degradation via the ubiquitination pathway; USP2 inhibits lung cancer cell invasion and migration by stabilizing ARID2 protein.\",\n      \"method\": \"IP-Mass Spectrometry, co-immunoprecipitation, immunofluorescent colocalization, CHX chase assay, ubiquitination assay, transwell/wound healing migration assay\",\n      \"journal\": \"BioMed research international\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — Co-IP and CHX chase plus ubiquitination assay, single lab, multiple orthogonal methods\",\n      \"pmids\": [\"36567903\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2016,\n      \"finding\": \"ARID2 represses CD44 promoter activity and protein expression in hepatocellular carcinoma cells; overexpression of ARID2 inhibits cell invasion and metastasis in vitro and tumor growth in vivo in nude mice, mediated at least in part through transcriptional repression of CD44.\",\n      \"method\": \"Luciferase reporter assay (CD44 promoter), Western blot, adenoviral ARID2 overexpression, cell migration assay, subcutaneous tumor xenograft in nude mice\",\n      \"journal\": \"Zhonghua gan zang bing za zhi\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 3 / Moderate — luciferase and Western blot supporting promoter repression, with in vivo validation, single lab\",\n      \"pmids\": [\"27095763\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2017,\n      \"finding\": \"HBx (HBV X protein) suppresses ARID2 transcription through ATOH1-binding elements in the ARID2 promoter region (nt-1040/nt-601); ectopic ATOH1 expression or mutation of ATOH1 binding sites partially abolishes HBx-triggered ARID2 repression, and ARID2 abrogates HBx-enhanced HCC cell migration and proliferation.\",\n      \"method\": \"Promoter deletion/luciferase assays, site-directed mutagenesis of ATOH1 binding sites, ectopic ATOH1 expression, Western blot, cell migration assays\",\n      \"journal\": \"Cancer science\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — luciferase with mutagenesis of binding sites and functional rescue experiments, single lab\",\n      \"pmids\": [\"28498550\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2020,\n      \"finding\": \"ARID2 haploinsufficiency is associated with enhanced RAS-MAPK (ERK1/2) activity; this is mediated through reduced IFITM1 expression, which normally interacts with caveolin-1 (CAV-1) to inhibit ERK activation. ARID2 KO in HeLa cells increases ERK1 and ERK2 phosphorylation; patient iPSCs show impaired neuronal differentiation with enhanced RAS-MAPK activity.\",\n      \"method\": \"Transient ARID2 knockout via shRNA (ERK phosphorylation), patient-derived iPSC differentiation assays, Arid2 haploinsufficient mice (CRISPR/Cas9), IFITM1/CAV-1 expression analysis\",\n      \"journal\": \"Journal of medical genetics\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — multiple model systems (cells, iPSCs, mice) with ERK phosphorylation readout, single lab\",\n      \"pmids\": [\"33051312\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2018,\n      \"finding\": \"NMR backbone resonance assignment of the ARID domain of human BAF200 (ARID2) was completed, providing secondary structure information; the ARID domain has the potential to bind DNA sequences with high affinity, though the exact DNA binding specificities within the PBAF context were not yet established.\",\n      \"method\": \"NMR spectroscopy (backbone 1H, 13C, 15N chemical shift assignment)\",\n      \"journal\": \"Biomolecular NMR assignments\",\n      \"confidence\": \"Low\",\n      \"confidence_rationale\": \"Tier 1 / Weak — NMR assignment only (no functional mutagenesis validation of DNA binding); single lab, preliminary structural work\",\n      \"pmids\": [\"30535613\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2024,\n      \"finding\": \"PBAF (defined by ARID2) occupies repressive chromatin regions co-bound by PRC2, and ARID2 loss disrupts PBAF complex formation, impairing REST transcription factor binding to its target loci. This leads to upregulation of synaptic/neuronal transcripts normally silenced by REST, a gene signature conserved in melanoma patients with ARID2 mutations.\",\n      \"method\": \"Comprehensive epigenomic profiling (ChIP-seq for SWI/SNF complexes), ARID2 knockout in melanoma cells and melanocytes, time-resolved chromatin accessibility assays, REST occupancy assays\",\n      \"journal\": \"bioRxiv\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — ChIP-seq with KO and REST occupancy validation, preprint not yet peer-reviewed\",\n      \"pmids\": [],\n      \"is_preprint\": true\n    },\n    {\n      \"year\": 2024,\n      \"finding\": \"ARID2 knockout in TFE3-rearranged renal cell carcinoma (TFE3-RCC) enhances ERBB3 expression; ChIP assay demonstrated that PRCC-TFE3 directly binds and upregulates ERBB3, and ARID2 KO further enhances this effect. ARID2-KO TFE3-RCC cells show increased MAPK and ERBB3 signaling activation and heightened sensitivity to ERBB3 inhibitor AZD8931.\",\n      \"method\": \"In vitro and in vivo ARID2 KO experiments, transcriptomic analysis, ChIP assay (PRCC-TFE3 binding to ERBB3), ERBB3 inhibitor sensitivity assays, migration/proliferation assays\",\n      \"journal\": \"Current issues in molecular biology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — ChIP assay with functional KO and inhibitor validation, single lab\",\n      \"pmids\": [\"39727945\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2025,\n      \"finding\": \"Arid2 is required for normal B cell differentiation in vivo; Mb1-Cre-mediated deletion causes marked reduction of splenic and circulating Follicular B cells through impaired differentiation (not proliferation or survival). Arid2 loss disrupts stage-specific gene expression programs in pro-B, pre-B, and Follicular B cells, with cumulative downregulation of B cell receptor signaling pathways, and functionally impairs germinal center expansion and IgG antibody production.\",\n      \"method\": \"Conditional KO mice (Mb1-Cre, CD19-Cre), flow cytometry, RNA-seq of isolated B cell populations, immunization assays, bone marrow transplantation\",\n      \"journal\": \"bioRxiv\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — multiple Cre systems with transcriptomic and functional immune readouts, preprint pending peer review\",\n      \"pmids\": [\"41256460\"],\n      \"is_preprint\": true\n    }\n  ],\n  \"current_model\": \"ARID2 (BAF200) is a defining subunit of the PBAF SWI/SNF chromatin-remodeling complex that regulates gene-selective transcription (including interferon-responsive genes via PBAF specificity), represses oncogenic targets (Snail via DNMT1 recruitment, cyclin D1/E1 via E2F1 displacement, CD44, HSPA1A, ERBB3), facilitates homologous recombination-based DNA repair by recruiting Rad51 and XPG to damage sites, promotes ubiquitin-mediated degradation of JAK2 (through CARM1/NEDD4L-dependent chromatin regulation), is itself degraded as a pomalidomide-induced CRL4CRBN neosubstrate (requiring BRD7), can be stabilized by the deubiquitinase USP2, and is required in vivo for cardiac morphogenesis, normal hematopoiesis, and B cell differentiation.\"\n}\n```","stage2_raw":"{\n  \"mechanistic_narrative\": \"ARID2 (BAF200) is a defining, gene-selectivity subunit of the PBAF SWI/SNF chromatin-remodeling complex that directs context-specific transcriptional programs in development, immunity, DNA repair, and tumor suppression [#0]. As a PBAF specificity factor it is required for activation of interferon-responsive genes and assembles into more than one PBAF configuration, including a canonical BRG1-containing form and a distinct BRG1-independent, BAF180-containing form [#0, #4]. Its ARID domain has the structural potential for high-affinity DNA binding [#18]. Beyond transcriptional activation, ARID2 acts as a transcriptional repressor of oncogenic and metastasis-promoting targets: it interacts with E2F1 to reduce E2F1/RNA Pol II occupancy of CCND1 and CCNE1 and slow G1/S progression [#2], recruits DNMT1 to methylate and silence the Snail promoter to suppress EMT and metastasis [#7], and represses CD44 and (in cooperation with PBAF/PRC2 chromatin) restrains additional gene programs [#15, #19]. ARID2 supports genome integrity through two repair pathways, enabling XPG accumulation for nucleotide excision repair and recruiting Rad51 to double-strand breaks for homologous recombination, and it co-maintains enhancer-promoter loops for BRCA1, RAD51, and 53BP1 [#3, #4, #13]. In vivo, ARID2 is required for cardiac morphogenesis and coronary artery development, fetal HSC expansion and erythropoiesis, lymphoid lineage commitment, and B cell differentiation [#1, #5, #10, #21]. ARID2 protein levels are regulated by the ubiquitin system: it is a pomalidomide-induced CRL4CRBN neosubstrate whose degradation requires the PBAF subunit BRD7, and it is stabilized by the deubiquitinase USP2 [#8, #14]. ARID2 haploinsufficiency is associated with enhanced RAS-MAPK (ERK1/2) signaling through reduced IFITM1, with patient iPSCs showing impaired neuronal differentiation [#17].\",\n  \"teleology\": [\n    {\n      \"year\": 2005,\n      \"claim\": \"Established ARID2 as a dedicated PBAF specificity subunit, answering whether PBAF and BAF complexes regulate distinct genes and which subunit confers that selectivity.\",\n      \"evidence\": \"Biochemical complex purification and in vivo transcription assays on interferon-responsive promoters\",\n      \"pmids\": [\"15985610\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Did not define which DNA sequences or cofactors ARID2 recognizes to confer specificity\", \"Generality beyond interferon-responsive genes untested\"]\n    },\n    {\n      \"year\": 2014,\n      \"claim\": \"Demonstrated an essential developmental requirement for ARID2 in heart and coronary vessel formation, moving it from a transcriptional factor to a physiological morphogenesis regulator.\",\n      \"evidence\": \"Conditional knockout mouse with embryonic histology and phenotyping\",\n      \"pmids\": [\"25299188\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Target genes driving the cardiac phenotype not defined\", \"Mechanism of subepicardial-to-arterial cell fate transition unresolved\"]\n    },\n    {\n      \"year\": 2016,\n      \"claim\": \"Defined a direct transcriptional-repressor mechanism for tumor suppression by linking ARID2 to E2F1-driven cell-cycle gene control and to CD44 repression.\",\n      \"evidence\": \"Co-IP, ChIP of E2F1/Pol II at CCND1/CCNE1, luciferase reporter, xenografts in HCC models\",\n      \"pmids\": [\"27351279\", \"27095763\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Whether repression requires intact PBAF remodeling activity not tested\", \"Direct ARID2 promoter occupancy versus indirect effects not fully separated\"]\n    },\n    {\n      \"year\": 2017,\n      \"claim\": \"Showed ARID2 is required for two distinct DNA repair pathways, explaining how its loss promotes mutagenesis and tumorigenesis.\",\n      \"evidence\": \"CRISPR KO with XPG recruitment assays (NER) and reciprocal Co-IP plus HR/Rad51 recruitment assays; identification of two PBAF subforms\",\n      \"pmids\": [\"28238438\", \"28381560\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Structural basis of ARID2-Rad51 and ARID2-XPG recruitment not resolved\", \"Relative contribution of NER versus HR to tumor phenotypes unclear\"]\n    },\n    {\n      \"year\": 2017,\n      \"claim\": \"Identified upstream transcriptional control of ARID2 itself, with HBV HBx repressing ARID2 via ATOH1 elements to promote HCC.\",\n      \"evidence\": \"Promoter deletion/luciferase, ATOH1 site mutagenesis, ectopic expression and migration assays\",\n      \"pmids\": [\"28498550\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Endogenous role of ATOH1 in normal ARID2 regulation untested\", \"Single-lab promoter-level evidence\"]\n    },\n    {\n      \"year\": 2018,\n      \"claim\": \"Provided the structural starting point for understanding ARID2-DNA recognition by assigning the ARID domain backbone.\",\n      \"evidence\": \"NMR backbone chemical shift assignment of the human BAF200 ARID domain\",\n      \"pmids\": [\"30535613\"],\n      \"confidence\": \"Low\",\n      \"gaps\": [\"No functional mutagenesis validating DNA binding\", \"DNA binding specificity within PBAF context not established\"]\n    },\n    {\n      \"year\": 2018,\n      \"claim\": \"Extended ARID2's essential roles to the hematopoietic system, establishing a tumor-suppressor function in leukemia and a requirement for HSC expansion and erythropoiesis.\",\n      \"evidence\": \"Multiple Cre conditional knockouts, fetal liver/BM transplantation, RNA-seq, MLL-AF9 leukemia model\",\n      \"pmids\": [\"29482581\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Direct transcriptional targets in HSCs not pinpointed\", \"Mechanism distinguishing erythroid versus stem-cell defects unclear\"]\n    },\n    {\n      \"year\": 2020,\n      \"claim\": \"Resolved the metastasis-suppressor mechanism in HCC by tying ARID2 to DNMT1-mediated Snail promoter silencing and mapping it to the C2H2 domain.\",\n      \"evidence\": \"KO mouse HCC models, ChIP of DNMT1, bisulfite sequencing, domain mutants, metastasis assays\",\n      \"pmids\": [\"32071245\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"How ARID2 physically recruits DNMT1 not structurally defined\", \"Whether this mechanism operates outside HCC untested\"]\n    },\n    {\n      \"year\": 2020,\n      \"claim\": \"Defined ARID2 protein-level regulation by the ubiquitin-proteasome system, identifying it as a pomalidomide-induced CRL4CRBN neosubstrate dependent on BRD7.\",\n      \"evidence\": \"Proteomics, Co-IP, BRD7 knockdown, pomalidomide degradation and MYC expression assays in myeloma\",\n      \"pmids\": [\"32958952\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Degron determinants on ARID2 not mapped\", \"Physiological (non-drug) triggers of CRL4CRBN-mediated ARID2 turnover unknown\"]\n    },\n    {\n      \"year\": 2020,\n      \"claim\": \"Connected ARID2 loss to anti-tumor immunity and to RAS-MAPK signaling, linking its chromatin function to STAT1/chemokine programs and IFITM1-CAV1 control of ERK.\",\n      \"evidence\": \"Melanoma KO with anti-PD-L1 treatment and CD8 infiltration; shRNA/KO with ERK phosphorylation, patient iPSC differentiation and haploinsufficient mice; lymphoid-lineage conditional KO with RNA-seq\",\n      \"pmids\": [\"33333124\", \"33051312\", \"33346030\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Direct chromatin targets bridging ARID2 to STAT1/IFITM1 not defined\", \"Whether immune and MAPK effects share a common transcriptional node unclear\"]\n    },\n    {\n      \"year\": 2021,\n      \"claim\": \"Identified a context-dependent driver downstream of ARID2 loss in lung adenocarcinoma, defining HSPA1A as a selective vulnerability.\",\n      \"evidence\": \"Kras GEMMs, integrated ChIP-seq/RNA-seq, HSPA1A knockdown and inhibitor in cells and animals\",\n      \"pmids\": [\"34858604\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Why HSPA1A dependency is ARID2-specific not mechanistically resolved\", \"Direct ARID2 occupancy at HSPA1A regulatory regions not detailed\"]\n    },\n    {\n      \"year\": 2022,\n      \"claim\": \"Uncovered a metabolic and signaling role by which ARID2 represses JAK2-STAT5-PPARgamma to limit hepatic steatosis through CARM1/NEDD4L-dependent JAK2 degradation.\",\n      \"evidence\": \"Liver-specific KO with HFD, ChIP of CARM1/H3R17me2a at NEDD4L, ubiquitination assays, JAK2 inhibitor rescue, clinical samples\",\n      \"pmids\": [\"36396719\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"How ARID2 selects the NEDD4L locus for CARM1 recruitment unresolved\", \"Relevance to non-hepatic tissues untested\"]\n    },\n    {\n      \"year\": 2022,\n      \"claim\": \"Revealed a therapeutic synthetic-lethal interaction, showing ARID2 and BRD4 jointly sustain DSB-repair gene enhancer loops.\",\n      \"evidence\": \"Drug screen with JQ1 in ARID2-depleted HCC, DSB and HR/NHEJ assays, chromatin conformation capture, BRCA1/RAD51/53BP1 expression\",\n      \"pmids\": [\"35017665\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Direct cooperative binding of ARID2 and BRD4 at the loops not shown\", \"Single-lab evidence\"]\n    },\n    {\n      \"year\": 2022,\n      \"claim\": \"Identified USP2 as a deubiquitinase that stabilizes ARID2, complementing the CRL4CRBN degradation axis.\",\n      \"evidence\": \"IP-MS, Co-IP, immunofluorescence colocalization, CHX chase, ubiquitination and migration assays\",\n      \"pmids\": [\"36567903\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"DUB cleavage site / ubiquitin linkage on ARID2 not mapped\", \"Single-lab, reciprocal in vivo validation limited\"]\n    },\n    {\n      \"year\": 2024,\n      \"claim\": \"Linked PBAF/ARID2 to repressive chromatin and REST function, and extended ARID2 tumor-suppressor logic to TFE3-RCC via ERBB3.\",\n      \"evidence\": \"ChIP-seq of SWI/SNF and REST occupancy in melanoma (preprint); ARID2 KO with PRCC-TFE3/ERBB3 ChIP and ERBB3 inhibitor sensitivity in TFE3-RCC\",\n      \"pmids\": [\"39727945\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Mechanism of PBAF-PRC2 co-occupancy at repressive regions not fully defined\", \"Melanoma REST findings remain in preprint\"]\n    },\n    {\n      \"year\": 2025,\n      \"claim\": \"Established a requirement for ARID2 in B cell differentiation and humoral immunity, refining its hematopoietic role to lineage-specific gene programs.\",\n      \"evidence\": \"Conditional KO (Mb1-Cre, CD19-Cre), flow cytometry, stage-specific RNA-seq, immunization and germinal center assays (preprint)\",\n      \"pmids\": [\"41256460\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Direct ARID2 targets controlling BCR-signaling genes not identified\", \"Findings remain in preprint pending peer review\"]\n    },\n    {\n      \"year\": null,\n      \"claim\": \"How ARID2 selects its genomic binding sites and recruits distinct effectors (DNMT1, CARM1, Rad51, XPG, E2F1) at different loci remains unresolved at the structural and biochemical level.\",\n      \"evidence\": \"No reconstitution or structural study in the timeline maps ARID2 site selection or effector hand-off\",\n      \"pmids\": [],\n      \"confidence\": \"Low\",\n      \"gaps\": [\"No DNA-binding specificity defined for the ARID/C2H2 domains in PBAF context\", \"No structure of ARID2 within an assembled PBAF complex\", \"Rules governing activator-versus-repressor outcomes unknown\"]\n    }\n  ],\n  \"mechanism_profile\": {\n    \"molecular_activity\": [\n      {\"term_id\": \"GO:0140110\", \"supporting_discovery_ids\": [0, 2, 7, 15]},\n      {\"term_id\": \"GO:0003677\", \"supporting_discovery_ids\": [18]},\n      {\"term_id\": \"GO:0060090\", \"supporting_discovery_ids\": [3, 4, 7, 12]}\n    ],\n    \"localization\": [\n      {\"term_id\": \"GO:0005634\", \"supporting_discovery_ids\": [0, 4, 7]},\n      {\"term_id\": \"GO:0000228\", \"supporting_discovery_ids\": [3, 4, 19]}\n    ],\n    \"pathway\": [\n      {\"term_id\": \"R-HSA-4839726\", \"supporting_discovery_ids\": [0, 4, 19]},\n      {\"term_id\": \"R-HSA-74160\", \"supporting_discovery_ids\": [0, 2, 7, 11]},\n      {\"term_id\": \"R-HSA-73894\", \"supporting_discovery_ids\": [3, 4, 13]},\n      {\"term_id\": \"R-HSA-1640170\", \"supporting_discovery_ids\": [2]},\n      {\"term_id\": \"R-HSA-168256\", \"supporting_discovery_ids\": [0, 9, 21]},\n      {\"term_id\": \"R-HSA-1266738\", \"supporting_discovery_ids\": [1, 5, 17, 21]},\n      {\"term_id\": \"R-HSA-392499\", \"supporting_discovery_ids\": [8, 12, 14]}\n    ],\n    \"complexes\": [\"PBAF SWI/SNF complex\"],\n    \"partners\": [\"E2F1\", \"DNMT1\", \"RAD51\", \"BRD7\", \"USP2\", \"CARM1\", \"BRD4\"],\n    \"other_free_text\": []\n  }\n}","audit_flag":null,"evaluation":{"pairwise":"win","faith_supported":8,"faith_total":8,"faith_pct":100.0}}